Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

February 17, 2025

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related
Terms Hide Related
Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2025 Feb 17;67(1722):e1 doi:10.58347/tml.2025.1722f

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.

Objective(s)

Upon completion of this activity, the participant will be able to:

Review the efficacy and safety of nemolizumab (Nemluvio) for treatment of atopic dermatitis.

Select a term to see related articles Adbry atopic dermatitis dupilumab Dupixent Ebglyss lebrikizumab Nemluvio nemolizumab tralokinumab

View the Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis

Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.